2011
The Cost of Integrated HIV Care and Buprenorphine/Naloxone Treatment: Results of a Cross-Site Evaluation
Schackman BR, Leff JA, Botsko M, Fiellin DA, Altice FL, Korthuis PT, Sohler N, Weiss L, Egan JE, Netherland J, Gass J, Finkelstein R. The Cost of Integrated HIV Care and Buprenorphine/Naloxone Treatment: Results of a Cross-Site Evaluation. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s76-s82. PMID: 21317599, PMCID: PMC3270565, DOI: 10.1097/qai.0b013e31820a9a66.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxone treatmentIntegrated care patientsBuprenorphine/naloxoneNaloxone treatmentCare patientsClinic costsIntegrated careCross-site evaluationHIV clinical sitesIntegrated HIV careUrine toxicology analysisMedian monthly costPotential cost offsetsToxicology analysisHIV careIntegrated HIVSimilar patientsPhysician encountersPatient costsClinic settingMedian numberProvider encountersPatient timePatientsClinical sites
2006
Models for Integrating Buprenorphine Therapy into the Primary HIV Care Setting
Basu S, Rohrberg D, Bruce RD, Altice FL. Models for Integrating Buprenorphine Therapy into the Primary HIV Care Setting. Clinical Infectious Diseases 2006, 42: 716-721. PMID: 16447120, DOI: 10.1086/500200.Peer-Reviewed Original ResearchConceptsBuprenorphine maintenance therapyHIV care settingsMaintenance therapyHIV servicesCare settingsPrimary HIV care settingsSite specialistHIV care providersInjection drug useHuman immunodeficiency virusNegative clinical outcomesPrimary care modelDrug treatment modelAntiretroviral therapyHIV careBuprenorphine therapyClinical outcomesImmunodeficiency virusClinic settingOpiate useCare modelCare providersOpiate dependenceDrug useTherapy services